"Take your medicine": Nonadherence issues in patients with ulcerative colitis

Gastroenterology Nursing

Volumn 30, Issue 3, 2007, Pages 212-217

  Turnbough, Lisa ^a,b   Wilson, Lindsay ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ATTITUDE TO HEALTH; CHEMISTRY; COST OF ILLNESS; DRUG COST; DRUG SELF ADMINISTRATION; ECONOMICS; HOSPITALIZATION; HUMAN; MOTIVATION; NURSE ATTITUDE; NURSING; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RECTAL DRUG ADMINISTRATION; REMISSION; REVIEW; STATISTICS; TREATMENT OUTCOME; TREATMENT REFUSAL; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATTITUDE TO HEALTH; CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; COST OF ILLNESS; DRUG COSTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MESALAMINE; MOTIVATION; NURSE'S ROLE; PATIENT EDUCATION; QUALITY OF LIFE; REMISSION INDUCTION; SELF ADMINISTRATION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 34250652077     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/01.SGA.0000278170.13059.e9     Document Type: Review

References (35)

1. Aumais, G., Lefebvre, M., Massicotte, J., Tremblay, C., Kasbo, J., Brunet, J. S., et al. (2005). Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis. Drugs R D, 6, 41-46.
2. Ayres, R. C., Gillen, C. D., Walmsley, R. S., & Allan, R. N. (1996). Links progression of ulcerative proctosigmoiditis: Incidence and factors influencing progression. European Journal of Gastroenterology and Hepatology, 8, 555-558.
3. Bassi, A., Dodd, S., Williamson, P., & Bodger, K. (2004). Cost of illness of inflammatory bowel disease in the UK: A single-centre retrospective study. Gut, 53, 1471-1478.
4. Brentnall, T. A. (2003). Molecular underpinnings of cancer in ulcerative colitis. Current Opinion in Gastroenterology, 19, 64-68.
5. Brunner, M., Greinwald, R., Kletter, K., Kvaternik, H., Corrado, M. E., Eichler, H. G., & Muller. M. (2003). Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labeled mesalazine pellets vs tablets in male healthy volunteers. Alimentary Pharmacologic Therapy, 17, 1163-1169.
6. Cleemput, I., & Kesteloot, K. (2002). Economic implications of noncompliance in health care. Lancet, 359, 2129-2130.
7. Eaden, J., Abrams, K., Ekbom, A., Jackson, E., & Mayberry, J. (2000). Colorectal cancer prevention in ulcerative colitis: A case-control study. Alimentary Pharmacologic Therapy, 14, 145-153.
8. Eisen, S. A., Miller, D. K., Woodward, R. S., Spitznagel, E., & Przybeck, T. R. (1990). The effect of prescribed daily dose frequency on patient medication compliance. Archives of Internal Medicine, 150, 1881-1884.
9. Fish, D., & Kugathasan, S. (2004). Inflammatory bowel disease. Adolescent Medical Clinic, 15, 67-90, ix.
10. Ghosh, S., Shand, A., & Ferguson, A., (2000). Ulcerative colitis. British Medical Journal, 320, 1119-1123.
11. Gionchetti, P., Ardizzone, S., Benvenuti, M. E., Bianchi Porro, G., Biasco, G., Cesari, P., et al. (1999). A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: A randomized controlled multicentre trial. Alimentary Pharmacologic Therapy, 13, 381-388.
12. Gionchetti, P., Rizzello, F., Habal, F., Morselli, C., Amadini, C., Romagnoli, R., & Campieri, M. (2003). Standard treatment of ulcerative colitis. Digestive Diseases, 21, 157-167.
13. Han, S. W., McColl, E., Barton, J. R., James, P., Steen, I. N., & Welfare, M. R. (2005). Predictors of quality of life in ulcerative colitis: The importance of symptoms and illness representations. Inflammatory Bowel Disease, 11, 24-34.
14. Hanauer, S. B., Sninsky, C. A., Robinson, M., Powers, B. J., McHattie, J. D., Mayle, J. E., et al. (1996). An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: A randomized, placebo-controlled trial. Annals of Internal Medicine, 124, 204-211.
15. Irvine, E. J. (2004). Review article: Patients' fears and unmet needs in inflammatory bowel disease. Alimentary Pharmacologic Therapy, 20(Suppl. 4), 54-59.
16. Janke, K. H., Klump, B., Gregor, M., Meisner, C., & Haeuser, W. (2005). Determinants of life satisfaction in inflammatory bowel disease. Inflammatory Bowel Disease, 11, 272-286.
17. Kamm, M., Sandborn, W. J., Gassull, M., Schreiber, S., & Jackowski, L. (2005). Comparison of the efficacy and safety of SPD476, a novel, once-daily, high-dose formulation of mesalamine, and Asacol with placebo for the induction of remission of mild-moderate ulcerative colitis: A phase III study. American Journal of Gastroenterology, 100(Suppl. 9), S291 (Abstract 786).
18. Kane, S. V. (2006). Systematic review: Adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacologic Therapy, 23, 577-585.
19. Kane, S. V., Cohen, R. D., Aikens, J. E., & Hanauer, S. B. (2001). Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology, 96, 2929-2933.
20. Kane, S. V., & Dang, J. (2004). Medication-taking behaviour in a gastroenterology clinic: A disconnect between patient behaviour and physician knowledge. Gastroenterology, 126, A605 (Abstract W1283).
21. Kane, S., De Vos, M., Riley, S., Frieri, G., & Mittmann, U. (2005). Compliance issues in inflammatory bowel disease. Review of Gastroenterology Disorders, 5, 101-106.
22. Kane, S., Huo, D., Aikens, J., & Hanauer, S. (2003). Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine, 114, 39-43.
23. Kornbluth, A., & Sachar, D. B. (2004). Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology, 99, 1371-1385.
24. Lamet, M., Ptak, T., Dallaire, C., Shah, U., Grace, M., Spenard, J., et al. (2005). Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: A multicenter randomized study. Inflammatory Bowel Disease, 11, 625-630.
25. Levy, R. L., & Feld, A. D. (1999). Increasing patient adherence to gastroenterology treatment and prevention regimens. American Journal of Gastroenterology, 94, 1733-1742.
26. Lichtenstein, G., Kamm, M., Sandborn, W. J., Boddu, P., & Gubergrits, N. (2005). SPD476 is a novel, once-daily, high-dose, effective and well-tolerated 5ASA formulation for the induction of remission of mild-to-moderate ulcerative colitis: A phase III study. American Journal of Gastroenterology, 100(Suppl. 9), S291-S292 (Abstract 787).
27. Lim, W. C., & Hanauer, S. B. (2004). Controversies with aminosalicylates in inflammatory bowel disease. Review of Gastroenterology Disorders, 4, 104-117.
28. Loftus, E. V., Jr., Silverstein, M. D., Sandborn, W. J., Tremaine, W. J., Harmsen, W. S., & Zinsmeister, A. R. (2000). Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival. Gut, 46, 336-343.
29. Martin, A., Leone, L., Castagliuolo, I., Di Mario, F., & Naccarato, R. (1992). What do patients want to know about their inflammatory bowel disease? Italian Journal of Gastroenterology, 24, 477-480.
30. Nielsen, O. H. (1982). Sulfasalazine intolerance: A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 17, 389-393.
31. Prantera, C., Viscido, A., Biancone, L., Francavilla, A., Giglio, L., & Campieri, M. (2005). A new oral delivery system for 5-ASA: Preliminary clinical findings for MMx. Inflammatory Bowel Disease, 11, 421-427.
32. Sartor, R. B. (2006) Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature Clinical Practice Gastroenterology & Hepatology, 3, 390-407.
33. van Hees, P. A., & van Tongeren, J. H. (1982). Compliance to therapy in patients on a maintenance dose of sulfasalazine. Journal of Clinical Gastroenterology, 4, 333-336.
34. Vermeire, E., Hearnshaw, H., van Royen, P., & Denekens, J. (2001). Patient adherence to treatment: Three decades of research: A comprehensive review. Journal of Clinical Pharmacy & Therapeutics, 26, 331-342.
35. Wilding, I., Behrens, C., Tardif, S., Wray, H., Bias, P., & Albrecht, W. (2003). Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Alimentary Pharmacologic Therapy, 17, 1153-1162.